Write a cosmetic objective before an acne-care label
Begin with the observable concern: excess-looking shine, visible pores, the appearance of marks or the finish and comfort of a product for blemish-prone skin. Specify which concern is primary and who the intended users are. Avoid using acne care as a substitute for a clear development brief.
FDA treats acne-treatment intended use as a drug question in the United States. This article concerns cosmetic appearance evaluation. Changing a label to blemish care does not by itself make treatment claims cosmetic; assess the complete intended use in the destination market.
Measure oiliness and pore appearance independently
A primary study comparing self-described oily and dry skin measured sebum, pore size and hydration separately. Its findings in the studied population did not make pore size interchangeable with sebum level. Use that distinction when choosing the questions for a new product study.
Keep shine ratings, instrumental surface-oil measurements and pore-image assessments as different endpoints. Choose repeatable sites, timing and preparation instructions. If the brief concerns the appearance of marks, distinguish color observations from changes in active blemishes and retain consistent image conditions.
| Cosmetic objective | Observation to plan | Result does not establish |
|---|---|---|
| Less visible shine | A defined shine or optical assessment | Acne treatment |
| Surface oiliness | A suitable sebum protocol | Reduced pore visibility without its own assessment |
| Pore appearance | Consistent image region and grading | A permanent anatomical change |
| Appearance of marks | Separate, consistent color or image observations | Treatment of active lesions |
| Comfort during use | Recorded tolerability and user observations | A general safety or non-comedogenic conclusion |
Source: Primary study: facial sebum, pore size and hydration
Decide whether cleansing or leave-on use is the study
For a cleanser, define application, contact, dilution and rinsing conditions, plus the delay before observations. For a leave-on product, define amount, area, frequency and the accompanying routine in the actual protocol. Results from one exposure pattern should not be transferred automatically to the other.
Keep relevant background products documented. Changes in cleanser, exfoliant, makeup or other treatments during a study can make the comparison difficult to interpret. Establish inclusion, exclusion and discontinuation procedures with a qualified study team rather than asking people to change medical care for a cosmetic trial.
Treat oil phase, surfactants and preservation as study variables
A matched control should keep the oil phase, surfactant blend, powders, solvents, preservative system, fragrance and process constant wherever possible. Remove the test variable with a documented mass-balance adjustment. If the control needs a different structuring system, explain the resulting limitation.
Do not infer the behavior of the finished base from an ingredient reputation. Plan the product-level assessment needed for the proposed wording. A non-comedogenic claim, if intended, needs its own appropriate substantiation rather than a list of ingredients presumed unlikely to clog pores.
Check the stored formula and the in-use pack
Follow uniformity, separation, precipitation, color, odor, pH and viscosity where relevant. Consider how settling, pump delivery or product remaining at a closure could affect use of the trial. Keep storage conditions and sample age attached to every observation.
Plan appropriate preservation and safety assessments for the complete product. Define how to record discomfort, redness or worsening appearance and when to stop use. Avoid interpreting a stronger sensation, extra dryness or a visible surface change as proof that the product is working.
Separate a mechanism experiment from the cosmetic outcome
An ingredient-level experiment can motivate a trial, but it does not answer whether the complete product improves the chosen appearance endpoint. Record the test model and exposure before comparing it with intended consumer use.
Keep efficacy, tolerability and claim interpretation in separate sections of the report. The EU claims criteria require evidence for the communicated product benefit. The observations should support only the endpoint and use conditions that were actually evaluated.
Finish with a usable development record
Predefine the primary comparison, observation times and criteria for continuing or reformulating. Retain control results, unfavorable findings and deviations from preparation or use instructions. Explain whether a finding is immediate, repeat-use or still inconclusive.
The handoff should identify the formula revision, all material lots, process conditions, pack, storage history, protocol and source data. Include the proposed cosmetic wording and unresolved evidence gaps. This framework gives the next formulator a question to reproduce, without offering an acne treatment plan or a fixed ingredient dose.
Sources & scope
- FDA: cosmetic and drug intended use
- Primary study: facial sebum, pore size and hydration
- EU cosmetic claims: evidence and limits
Technical and regulatory references reviewed October 4, 2026. The cited methods and jurisdiction-specific guidance inform this development framework. They do not validate a PINHONBIO ingredient or finished formula. Study design, safety assessment and claim review must fit the actual product and market. General evaluation recommendations are editorial perspectives, not reported PINHONBIO test results.